Sugi Predict

Sugi Predict / Compounds / SCHEMBL2882652

SCHEMBL2882652

SCHEMBL2882652

COc1ncnc2ccc(C=C3SC(=O)NC3=O)cc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 5/20 0.56
▸ PIM2 Q9P1W9 4/20 0.56
▸ DYRK1A Q13627 3/20 0.56
▸ PIK3CD O00329 2/20 0.56
▸ CSNK2A2 P19784 2/20 0.56
▸ PIK3CA P42336 2/20 0.56
▸ PIK3CB P42338 2/20 0.56
▸ MTOR P42345 2/20 0.56
▸ PIK3CG P48736 2/20 0.56
▸ CLK1 P49759 2/20 0.56
▸ NPC1 O15118 2/20 0.56
▸ RAB9A P51151 2/20 0.56
▸ CSNK2A1 P68400 2/20 0.56
▸ PIM3 Q86V86 2/20 0.56
▸ MAOB P27338 1/20 0.56
▸ CSNK2B P67870 1/20 0.56
▸ DYRK2 Q92630 1/20 0.56
▸ CISD1 Q9NZ45 1/20 0.56
▸ DYRK1B Q9Y463 1/20 0.56
▸ PDE4B Q07343 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2882650 1.00 PIM1 (0.56) PIM1PIM2DYRK1APIK3CDCSNK2A2
SCHEMBL12975474 1.00 PIM1 (0.56) PIM1PIM2DYRK1APIK3CDCSNK2A2
SCHEMBL4636794 0.92 PIM1 (0.48) PIM1PIM2DYRK1APIK3CDCSNK2A2
SCHEMBL4636797 0.92 PIM1 (0.48) PIM1PIM2DYRK1APIK3CDCSNK2A2
SCHEMBL2880429 0.81 CISD1 (0.60) PIM1PIM2DYRK1APIK3CDCSNK2A2
SCHEMBL2880427 0.81 CISD1 (0.60) PIM1PIM2DYRK1APIK3CDCSNK2A2
SCHEMBL2877560 0.81 CISD1 (0.56) PIM1PIM2DYRK1APIK3CDCSNK2A2
SCHEMBL12975471 0.81 CISD1 (0.56) PIM1PIM2DYRK1APIK3CDCSNK2A2
SCHEMBL2882373 0.81 CISD1 (0.60) PIM1PIM2DYRK1APIK3CDCSNK2A2
SCHEMBL2882375 0.81 CISD1 (0.60) PIM1PIM2DYRK1APIK3CDCSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7846925-B2 Azolidinone-vinyl fused-benzene derivatives MERCK SERONO SA (CH) 2010-12-07 — — US claimed
US-20090042773-A1 P13 kinase gamma inhibitors for the treatment of anaemia MERCK SERONO SA (CH) 2009-02-12 — — US claimed
EP-1807075-A2 PI3 KINASE GAMMA INHIBITORS FOR THE TREATMENT OF ANAEMIA Applied Research Systems ARS Holding N.V. (AN) 2007-07-18 — — EP claimed
US-20060122176-A1 Azolidinone-vinyl fused-benzene derivatives MERCK SERONO SA (CH) 2006-06-08 — — US claimed
WO-2006040318-A2 PI3 KINASE GAMMA INHIBITORS FOR THE TREATMENT OF ANAEMIA APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2006-04-20 — — WO claimed
US-20050222225-A1 Use of compounds for increasing spermatozoa motility APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) 2005-10-06 — — US claimed
EP-1549644-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES Applied Research Systems ARS Holding N.V. (AN) 2005-07-06 — — EP claimed
EP-1531813-A1 USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY Applied Research Systems ARS Holding N.V. (AN) 2005-05-25 — — EP claimed
WO-2004007491-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2004-01-22 — — WO claimed
WO-2004006916-A1 USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY APPLIED RESEARCH SYSTEMS ARS HOLDING NV (AN) 2004-01-22 — — WO claimed
US-7846925-B2 Azolidinone-vinyl fused-benzene derivatives MERCK SERONO SA (CH) 2010-12-07 — — US disclosed
US-20090306069-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES LABORATOIRES SERONO S.A. (CH) 2009-12-10 — — US disclosed
US-20080306057-A1 P13K Inhibitors for the Treatment of Endometriosis LABORATORIES SERONO SA (CH) 2008-12-11 — — US disclosed
US-20060122176-A1 Azolidinone-vinyl fused-benzene derivatives MERCK SERONO SA (CH) 2006-06-08 — — US disclosed
US-20050222225-A1 Use of compounds for increasing spermatozoa motility APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) 2005-10-06 — — US disclosed
EP-1549644-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES Applied Research Systems ARS Holding N.V. (AN) 2005-07-06 — — EP disclosed
EP-1531813-A1 USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY Applied Research Systems ARS Holding N.V. (AN) 2005-05-25 — — EP disclosed
WO-2004007491-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2004-01-22 — — WO disclosed
WO-2004006916-A1 USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY APPLIED RESEARCH SYSTEMS ARS HOLDING NV (AN) 2004-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306069-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES ZAP70, BRCA1, ZYX PIM1 2247/4885PIM2 2814/4885DYRK1A 3161/4885
US-20090042773-A1 P13 kinase gamma inhibitors for the treatment of anaemia PDPK1, PRKD3, PRKD1 PIM1 201/4885PIM2 264/4885DYRK1A 362/4885
US-20050222225-A1 Use of compounds for increasing spermatozoa motility CATSPER1, PI4KB, MAN2B2 PIM1 2811/4885PIM2 2494/4885DYRK1A 4508/4885
US-20080306057-A1 P13K Inhibitors for the Treatment of Endometriosis PDPK1, PIK3R4, MAP3K3 PIM1 864/4885PIM2 1010/4885DYRK1A 1259/4885
US-20060122176-A1 Azolidinone-vinyl fused-benzene derivatives BRCA1, ZAP70, F13B PIM1 2412/4885PIM2 2938/4885DYRK1A 3215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.